Jubilant Pharmova Limited · NSE:JUBLPHARMA

Jubilant Pharmova — Jubilant Life Sciences — Q1 FY2020 Earnings Presentation

17 slides from Jubilant Pharmova's earnings presentation, Jul 26, 2019

  1. Slide 1: Financial Results Quarter Ended June 30, 2019

    Financial Results Quarter Ended June 30, 2019

  2. Slide 2: Disclaimer

    Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f

  3. Slide 3: Conference Call Details

    Conference Call Details Date : July 26, 2019 Time : 05:00 pm IST Replay from : July 26 to August 2, 2019 Dial in No.: +91 22 7194 5757 Playback ID: 90561# 22

  4. Slide 4: Q1'FY20 Results Analysis

    ww Mirescncts Q1’FY20 Results Analysis

  5. Slide 5: Chairmen's Message

    Chairmen’s Message JUBILANT Q1’FY20 PERFORMANCE Revenue at Rs. 2,182 Crore up 5% YoY; EBITDA at Rs 444 Crores down 1% YoY PAT at Rs 185 Crore down 9% YoY with EPS of Rs. 11.6 per share vs Rs 13.0 per share last year Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari

  6. Slide 6: Corporate Announcement

    Corporate Announcement Evaluation of options to create focused entities for JLL businesses The board of directors of the Company (“Board”) considered the option of reorganizing its businesses with the following objectives: (a) create separate and focused entities for Pharmaceuticals and Life Science

  7. Slide 7: JLL – Q1'FY20 Financial Highlights

    JLL – Q1’FY20 Financial Highlights YoY Highlights Q1FY19 Q1FY20 Change (%)  Revenue at Rs 2,182 Crore up by 5% YoY Revenue Pharmaceuticals 1,181 1,321 12% • Pharmaceuticals revenue at Rs 1,321 Crore, up 12% YoY, Life Science Ingredients 847 805 (5%) contributing 61% to revenues Others 51 56 10% • L

  8. Slide 8: Adjusted Earnings

    Adjusted Earnings Consol EBITDA Rs Crore S. No. Q1FY19 Q1FY20 % Change YoY 1 Reported EBITDA 447 444 (1%) 2 One-off Adjustments 5 48 3 Adjusted EBITDA 452 493 9% 4 Reported EBITDA Margin 21.5% 20.4% 5 Adjusted EBITDA Margin 21.8% 22.6% One-off Expenses S. No. Particulars Q1FY19 Q1FY20 Site remediati

  9. Slide 9: Pharmaceuticals Segment Highlights – Q1'FY20 (1/2)

    Pharmaceuticals Segment Highlights – Q1’FY20 (1/2) Particulars Q1FY19 Q1FY20 % Change  Pharmaceuticals revenue at Rs 1,321 Crore, up 12% YoY, contributing Revenue 1,181 1,321 12% 61% to revenues Specialty Pharma 666 725 9% • Revenue growth was led by 24% YoY growth in CDMO and 9% increase in Specia

  10. Slide 10: Pharmaceuticals Segment Highlights – Q1'FY20 (2/2)

    Pharmaceuticals Segment Highlights – Q1’FY20 (2/2) USFDA Inspection Details CDMO Facility Last Inspection CMO  Strong growth in CMO business led by higher capacities, better on-time Montreal, CMO May, 2018 delivery compliance and operational efficiencies Montreal, Radiopharma Sep, 2017  Initiative

  11. Slide 11: LSI Segment Highlights – Q1'FY20

    LSI Segment Highlights – Q1’FY20 Particulars Q1FY19 Q1FY20 % Change  LSI revenue at Rs 805 Crore, down 5% YoY, contributing 37% to revenues Revenue 847 805 (5%)  LSI Adjusted EBITDA at Rs 130 Crore up 19% YoY with a margin of 16.2% as compared to Specialty Intermediates 235 279 19% 12.9% in Q1 las

  12. Slide 12: Others Segment Highlights – Q1'FY20

    Others Segment Highlights – Q1’FY20 Particulars Q1FY19 Q1FY20 % Change  Others segment revenue up 10% YoY to Rs 56 Crore led by growth Revenue 51 56 10% in Drug Discovery and Development Solutions (DDDS) business DDDS 45 48 8% • DDDS revenue grew by 8% driven by gain in new customer IBP 6 8 28% acc

  13. Slide 13: Drug Discovery and Development Solutions (DDDS)

    Drug Discovery and Development Solutions (DDDS) Status of Proprietary Products  We have an asset light, capital efficient, semi-virtual biotech business model with core strategy of developing novel and targeted small molecule therapies primarily in the area of Oncology and Auto-Immune disorders. 

  14. Slide 14: Debt Profile

    Debt Profile Particulars 31/03/19 30/06/19 Foreign Currency Loans ($ Mn) ($ Mn) Standalone 0 0 Subsidiaries 500 500 Total 500 500 Rupee Loans (Rs. Crs) (Rs. Crs) Standalone 1,341 1,056 Subsidiaries 61 95 Total 1,402 1,151 Gross Debt (Rs. Crs) (Rs. Crs) Standalone 1,341 1,056 Subsidiaries 3,519 3,546

  15. Slide 15: Appendix

    Ww Mirescncts Appendix 14

  16. Slide 16: Income Statement – Q1'FY20

    Income Statement – Q1’FY20 Particulars Q1 FY 19 Q1 FY20 YoY Growth (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 2,079 2,182 5% Pharmaceuticals 1,181 1,321 12% Life Science Ingredients 847 805 (5%) Others 51 56 10% Total Expenditure 1,641 1,747 6% Other Income 9 10 2% Segment EBITDA 454

  17. Slide 17: For more information

    For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002 Ph: +91 22 6645 1209 E-mail: ravi.agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Gaurav Kashyap Jubilant Life Sciences Limited Perfect Relat

Jubilant Life Sciences — Q1 FY2020 Earnings Presentation on 6ix